TrialAnnals of surgical oncology2022

Outcomes of a Phase II Study of Intraperitoneal Paclitaxel plus Systemic Capecitabine and Oxaliplatin (XELOX) for Gastric Cancer with Peritoneal Metastases.

Daryl K A Chia et al.PubMed ↗Publisher ↗

No numbers read from the abstract.